Evidence map›Paper›PMID 29436251›Full record

Observational studyJournal of diabetes science and technology2018

Improvement of Metabolic Control and Diabetes Management in Insulin-Treated Patients Results in Substantial Cost Savings for the German Health System.

Katharina Fritzen, Bettina Gutschek, Benedikte Coucke, Katerina Zakrzewska, Michael Hummel, Oliver Schnell

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Journal of diabetes science and technology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Katharina Fritzen1 Sciarc Institute, Baierbrunn, Germany.
Bettina Gutschek2 Johnson & Johnson Medical GmbH, Neuss, Germany.
Benedikte Coucke3 Johnson & Johnson Medical GmbH, Beerse, Belgium.
Katerina Zakrzewska4 Johnson & Johnson Diabetes Care Companies, Cilag GmbH Int, Zug, Switzerland.
Michael Hummel5 Forschergruppe Diabetes e.V., Helmholtz Centre Munich, Munich-Neuherberg, Germany.
Oliver Schnell1 Sciarc Institute, Baierbrunn, Germany.
Helmholtz Zentrum München · DEJohnson & Johnson (Germany) · DEJohnson & Johnson (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSelf-monitoring of blood glucose (SMBG) using the ColourSure™ Technology to visualize target range showed improvement of metabolic control and overall diabetes self-management in insulin-treated patients. This economic analysis aimed to identify cost savings for the German health system resulting from an HbA1c reduction due to the utilization of user-friendly glucose meters.

methodsPatient data from a recently published observational study on SMBG were used for risk evaluations using the UKPDS risk engine. These values were integrated in an economic analysis regarding costs of myocardial infarctions (MIs) related to diabetes for the German health system. Based on an earlier assessment these calculations were combined with a 10% reduction of severe hypoglycemic episodes. In the current study, 0% severe hypoglycemic episodes were observed.

resultsAn HbA1c reduction of 0.69% over 6 months was associated with a 3% decreased risk of MI in 10 years. In this model the decrease led to cost savings of €4.90 per patient-year. Considering 2.3 million insulin-treated patients in Germany, this 3% reduction of MI could result in annual savings of €11.27 million. Combining this with a 10% reduction in severe hypoglycemic events, the cost savings would increase to €30.61 per patient-year or €70.4 million for 2.3 million insulin-treated patients in Germany.

conclusionThe improvement of metabolic control and diabetes self-management that was achieved with the ColourSure™ Technology has the potential to generate substantial cost savings for the German health system underlining the importance of user-friendly methods for SMBG.

Indexed as

Diabetes MellitusAdultAgedBlood GlucoseBlood Glucose Self-MonitoringCost SavingsDiabetes ComplicationsFemaleGermanyGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulinMaleMiddle AgedBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinColourSure™ TechnologyDiabetesEconomic AnalysisSelf-Monitoring of Blood Glucose

Identifiers

PMID29436251
PMCPMC6134610
OpenAlexW2794134707

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.